From what 8 stock analysts predict, the share price for Intellia Therapeutics Inc (NTLA) might increase by 160.45% in the next year. This is based on a 12-month average estimation for NTLA. Price targets go from $49.00 to $95.00. The majority of stock analysts believe NTLA is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
NTLA is a stock in Health Care which has been forecasted to be worth $72.25 as an average. On the higher end, the forecast price is $95.00 USD by yanan zhu from Wells Fargo and on the lower end NTLA is forecasted to be $49.00 by william pickering from Bernstein.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
whitney ijem Canaccord Genuity | Buy | $72.0 | maintained | Feb 15, 2024 |
william pickering Bernstein | Buy | $49.0 | reiterated | Jan 10, 2024 |
jay olson Oppenheimer | Buy | $70.0 | maintained | Jan 9, 2024 |
kostas biliouris BMO Capital | Buy | $62.0 | rated | Jan 8, 2024 |
dae gon ha Stifel Nicolaus | Buy | $80.0 | maintained | Jan 8, 2024 |
luca issi RBC Capital | Buy | $70.0 | maintained | Jan 7, 2024 |
mani foroohar Leerink Partners | Buy | None | maintained | Jan 5, 2024 |
yanan zhu Wells Fargo | Buy | $95.0 | maintained | Jan 5, 2024 |
greg harrison Bank of America Securities | Buy | $80.0 | maintained | Jan 4, 2024 |
terence flynn Morgan Stanley | Buy | $85.0 | maintained | Nov 13, 2023 |
joon lee Truist Financial | Buy | $120.0 | maintained | Nov 12, 2023 |
geulah livshits Chardan Capital | Buy | $94.0 | reiterated | Nov 10, 2023 |
david lebovitz Citi | Hold | $31.0 | maintained | Nov 10, 2023 |
silvan tuerkcan JMP Securities | Hold | None | maintained | Nov 10, 2023 |
gena wang Barclays | Buy | $76.0 | maintained | Nov 10, 2023 |
salveen richter Goldman Sachs | Buy | $136.0 | maintained | Nov 10, 2023 |
joseph thome TD Cowen | Buy | None | maintained | Nov 9, 2023 |
jack allen Robert W. Baird | Hold | $38.0 | maintained | Oct 18, 2023 |
brian cheng J.P. Morgan | Buy | $74.0 | maintained | Oct 2, 2023 |
rick bienkowski Cantor Fitzgerald | Buy | $65.0 | reiterated | Aug 29, 2023 |
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
When did it IPO
2016
Staff Count
598
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. John M. Leonard M.D.
Market Cap
$2.48B
In 2023, NTLA generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that NTLA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
PRVA-USD
$20.93
BMBL-USD
$13.1
$6.62
$51.91
PSMT-USD
$80.24
PRFT-USD
$70.33